Role of the Shiga toxin in the hemolytic uremic syndrome;Papel de la toxina shiga en el sindrome uremico hemolitico

Medicina

Volumn 66, Issue SUPPL. 3, 2006, Pages 11-15

  Creydt, Virginia Pistone ^a   Nuñez, Pablo ^a   Boccoli, Javier ^a   Silberstein, Claudia ^a   Zotta, Elsa ^a   Goldstein, Jorge ^a   Ibarra, Cristina ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Brain damage; Diarrhea; HUS; Renal failure; Shiga toxin

Indexed keywords

ACUTE KIDNEY FAILURE; ARGENTINA; BACTERIUM CONTAMINATION; BLOODY DIARRHEA; CATTLE; CHRONIC KIDNEY FAILURE; CYTOTOXICITY; DIARRHEA; ENTEROBACTER INFECTION; FECES; FOOD CONTAMINATION; HEMOLYTIC UREMIC SYNDROME; HEMORRHAGIC COLITIS; HUMAN; NONHUMAN; PATHOGENESIS; PEDIATRICS; PUBLIC HEALTH; REVIEW; RISK REDUCTION; SHIGA TOXIN PRODUCING ESCHERICHIA COLI; SYMPTOMATOLOGY;

CENTRAL NERVOUS SYSTEM; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; ESCHERICHIA COLI VACCINES; HEMOLYTIC-UREMIC SYNDROME; HUMANS; INTESTINES; KIDNEY; SHIGA TOXINS;

EID: 33845783265     PISSN: 00257680     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Repetto HA: Long-term course and mechanisms of progression of renal disease in hemolytic uremic syndrome. Kidney Internat 2005; 97: S102-S106.
2. Jackson M, Neill R, O'Brien. AD, Holmes R, Newland J: Nucleotide sequence analysis and comparison of the structural genes for Shiga-like toxin I and Shiga-like toxin II encoded by bacteriophages from E coli 933. FEMS Microbiol Lett 1987; 44:109-4.
3. Melton-Celsa AR, Kokai-Kun JF, O'Brien AD: Activation of Shiga toxin type 2d (Stx2d) by elastase involves cleavage of the C-terminal two amino acids of the A2 peptide in the context of the appropiate B pentamer. Mol Microbiol 2002; 43: 207-15.
4. Jacewicz MS, Acheson DW, Mobassaleh M, Donohue-Rolfe A, Balasubramanian KA, Keusch GT: Maturational regulation of globotriaosylceramide, the Shiga-like toxin 1 receptor, in cultured human gut epithelial cells. J Clin Invest 1995; 96: 1328-35.
5. Sandvig K, Van Deurs. B: Endocytosis, intracellular transport, and cytotoxic action of Shiga toxin and ricin. Physiol Rev 1996; 76: 949-66.
6. Endo Y, Tsurugi K, Yutsudo T , Takeda Y, Ogasawara K, Igarashi K: Site of action of a Vero toxin (VT2) from E coli O157:H7 and of Shiga toxin on eukaryotic ribosomes. RNA N-glycosidase activity of the toxins. Eur J Biochem 1988; 171: 335-7.
7. Smith WE, Kane AK, Campbell ST, Acheson DWK, Cochran BH, Thorpe CM: Shiga toxin 1 triggers a ribotoxic stress response leading to p38 and JNK activation and induction of apoptosis in intestinal epithelial cells. Infect Immun 2003; 71: 1497-504.
8. Sandvig K, Garred O, Prydz K, Kozlov JV, Hansen SH, Van Deurs B: Retrogade transport of endocytosed Shiga Toxin to the endoplasmic reticulum. Nature 1992; 358: 510-11.
9. Sandvig K, Ryd M, Garred O, Schweda E, Holm PK, Van Deurs B: Retrogade transport from the Golgi complex to the ER of both Shiga toxin and the non-toxic Shiga B-fragment is regulated by butyric acid and cAMP. J Cell Biol 1994; 126: 53-64.
10. Falguieres T, Mallard F, Baron C, et al. Targeting of Shiga toxin B-subunit to retrograde transport route in asso-ciation with detergent-resistant membranes. Mol Biol Cell 2001; 12: 2453-68.
11. Garred O, Van Deurs B, Sandvig K: Furin-induced cleavage and activation of Shiga toxin. J Biol Chem 1995; 270: 10817-21.
12. Lea N, Lord JM, Roberts LM: Proteolytic cleavage of the A subunit is essential for maximal cytotoxicity of Escherichia coli O157:H7 Shiga-like toxin-1. Microbiol 1999; 145: 999-1004.
13. Garred O, Dubinina E, Holm PK, et al. Role of processing and intracellular transport for optimal toxicity of Shiga toxin and toxin mutants. Exp Cell Res 1995; 218: 39-49.
14. Philpott DJ, Ackerley CA, Kiliaan AJ, Karmali MA, Perdue MH, Sherman PM: Trnaslocation of verotoxin-1 across T84 monolayers: mechanism of bacterial toxin penetration of epithelium. Am J Physiol 1997, 273: G1349-58.
15. Schüller S, Frankel G, Phillips AD: Interaction of Shiga toxin from Escherichia coli with human intestinal epithelial cell lines and explants; Stx2 induces epithelial damages in organ culture. Cellular Microbiol 2004; 6: 289-301.
16. Núñez P, Pistone Creydt V, Bibini M, Ibarra C. Acción citotóxica de la toxina Shiga tipo 2 (Stx2) dependiente e independiente de Gb3 en modelos celulares de epitelio intestinal humano. Medicina (Buenos Aires) 2005; 65: 86.
17. Acheson D, Moore R, De Breucker S, et al. Translocation of Shiga toxin across polarized intestinal cells in tissue culture. Infect Immun 1996; 64: 3294-300.
18. Imai Y, Fukui T, Kurohane K, et al. Restricted expression of Shiga toxin binding sites on mucosal epithelium of mouse distal colon. Infect Immun 2003; 71: 985-90.
19. Fiorito P, Burgos J, Fernández Miyakawa M, Rivas M, Chillemi G, Berkowski D, Zotta E, Silberstein C, Ibarra C: Effect of Shiga toxin 2 on water and ion transport in the human colon in vitro. Dig Dis Sc 2000; 45: 480-6.
20. Slutsker L, Ries AA, Greene KD, Wells JG, Hutwagner L, Griffin PM: Escherichia coli O157:H7 diarrhea in the United States: clinical and epidemiologic features. Ann Intern Med 1997: 126: 505-13.
21. Hurley BP, Thorpe CM, Acheson DW: Shiga toxin translocation across intestinal epithelial cells is enhanced by neutrophil transmigration. Infect Immun 2001; 69: 6148-55.
22. Pistone Creydt V, Martín F, Fernández Miyakawa M, Zotta E, Silberstein C, Ibarra C. Shiga toxin 2 B subunit inhibits net fluid absorption in human colon and elicits fluid accumulation in rat colon loops. Brazilian J Med Biol Res 2004; 37: 799-808.
23. Hughes AK, Stricklett PK, Kohan DE. Cytotoxic effect of Shiga toxin-1 on human proximal tubules cells. Kidney Internat 1998; 54: 426-37.
24. Taguchi T, Uchida H, Kiyokawa N, et al: Verotoxins induce apoptosis in human renal tubular epithelium derived. Kidney Internat 1998; 53: 1681-8.
25. Karpman D, Andreasson A, Thysell H, Kaplan BS, Svanborg C: Cytokines in childhood hemolytic uremic syndrome and thrombotic thrombocytopenic purpura. Pediatr Nephrol 1995; 9: 694-9.
26. Karpman D, Hakansson A, Perez MT, Isaksson C, Carlemalm E, Caprioli A, Svanborg C: Apoptosis of renal cortical cells in the hemolitic-uremic syndrome: in vivo and in vitro studies. Infect Immun 1998; 66: 636-44.
27. Kiyokawa N, Taguchi T, Mori T, et al. Induction of apoptosis in normal renal tubular epithelial cells by Escherichia coli Shiga toxin 1 and 2. J Infect Dis 1998; 178: 178-84.
28. Cherla RP, Sang-Yun L, Tesh VL: Shiga toxins and apoptosis. FEMS Microbiol Lett 2003; 228: 159-66.
29. Pistone Creydt V, Silberstein C, Zotta E, Ibarra C: Cytotoxic effect of Shiga toxin-2 holotoxin and its B subunit on human renal tubular epithelial cells. Microbe Infec 2006, 8: 410-19.
30. Karpman D, Adreasson A, Thysell H, Kaplan BS, Svanborg C: Cyokines in childhood hemolytic uremic syndrome and thrombotic thrombocytopenic purpura. Pediatr Nephrol 1995; 9: 694-9.
31. López EL, Contrini MM, Devoto S, et al. Tumor necrosis factor concentrations in hemolytic uremic syndrome patients and children with bloody diarrhea in Argentina. Pediatr Infect Dis J 1995; 14: 594-8.
32. Comité de Nefrología: Incidencia del Síndrome Urémico Hemolítico (SUH) en la República Argentina. Arch Arg Pediatría 1995; 93: 407-11.
33. Richardson SE, Karmali MA, Becker LE, Smith CR: The histopathology of the hemolytic uremic syndrome associated with verocytotoxin-producing E. coli. Hum Pathol 1988; 19: 1102-8.
34. Fujii J, Kita T, Yoshida S, et al. Direct evidence of neuron impairment by oral infection with verotoxin-producing Escherichia coli O157:H- in mitomycin-treated mice. Infect Immun 1994; 62: 3447-53.
35. Fujii J, Kinoshita Y, Kita T, et al. Magnetic resonance imaging and histopathological study of brain lesions in rabbits given intravenous verotoxin 2. Infect Immun 1996; 64: 5053-60.
36. Fujii J, Kinoshita Y, Yamada Y, et al. Neurotoxicity of intrathecal Shiga toxin 2 and protection by intrathecal injection of anti-Shiga toxin 2 antiserum in rabbits. Microb Pathog 1998: 25: 139-46.
37. Núñez P, Pistone Creydt V, Bibini M, Ibarra C. Acción citotóxica de la toxina Shiga tipo 2 (Stx2) dependiente e independiente de Gb3 en modelos celulares de epitelio intestinal humano. Medicina (Buenos Airs) 2005; 65: 86.
38. Goldstein J, Pistone Creydt V, Loidl FC, Lopez-Costa JJ, Javier Boccoli J, Ibarra C: Intracerebroventricular administration of Shiga toxin type 2 altered neuroglial ultrastructures and changed the expression levels of nitric oxide synthase and glial fibrillary acidic protein. In VTEC2006 6th Internat Symposium on Shiga toxin (Verocytotoxin) producing Escherichia coli infections. Melbourne, Australia.
39. Trachtman H, Cnaan A, Christen E, et al. Effect of an oral Shiga toxin-binding agent on diarrhea-associated hemolytic uremic syndrome in children: a randomized controlled trial. JAMA 2003; 290: 1337-44.
40. Thorpe CM: Shiga toxin-producing Escherichia coli infection. Clin Infect Dis 2004; 38: 1299-303.
41. Castro-Parodi M, Levi L, Ibarra C: Neutralización de la acción de la toxina Shiga por un péptido de Stx2B que no tiene efecto citotóxico per se. Medicina (Buenos Aires) 2005; 65: 108.
42. Okuda T, Tokuda N, Numata S-I, et al. Targeted disruption of Gb3/DC77 syntha-se gene resulted in the complete deletion of globo-series glycosphingolipids and loss of sensitivity to verotoxins. J Biol Chem 2006; 281: 10230-5.